[go: up one dir, main page]

AR052446A1 - Piperidinas 3,4-sustituidas - Google Patents

Piperidinas 3,4-sustituidas

Info

Publication number
AR052446A1
AR052446A1 ARP050105578A ARP050105578A AR052446A1 AR 052446 A1 AR052446 A1 AR 052446A1 AR P050105578 A ARP050105578 A AR P050105578A AR P050105578 A ARP050105578 A AR P050105578A AR 052446 A1 AR052446 A1 AR 052446A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkyl
formula
hydroxyl
Prior art date
Application number
ARP050105578A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR052446A1 publication Critical patent/AR052446A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1) en donde: R1 es H, alquilo insustituido o sustituido, alquenilo insustituido o sustituido, alquinilo insustituido o sustituido, arilo insustituido o sustituido, heterociclilo insustituido o sustituido, o cicloalquilo insustituido o sustituido; R2 es alquilo insustituido o sustituido, alquenilo insustituido o sustituido, alquinilo insustituido o sustituido, arilo insustituido o sustituido, heterociclilo insustituido o sustituido, cicloalquilo insustituido o sustituido, o acilo; W es una fraccion seleccionada a partir de aquellas de las formulas (1A), (1B), y (1C) en donde el asterisco (*) denota la posicion en donde se enlaza la fraccion W con el átomo de C-4 en el anillo d3 piperidina de la formula (1), y en donde: X1, X2, X3, X4, y X5 se seleccionan independientemente a partir de C y N, en donde X4 en la formula 1B, y X1 en la formula 1C pueden tener uno de estos significados, o se pueden seleccionar adicionalmente a partir de S y O, en donde los átomos de C y N del anillo pueden llevar el numero requerido de H o sustituyentes R3 o - si está presente dentro de las limitaciones dadas más adelante- R4 para completar el numero de enlaces que surjan desde un C del anillo hasta 4, desde un N del anillo hasta 3; con la condicion de que, en la formula 1A, cuando menos 2, y de preferencia cuando menos 3 de X1 a X5 son C, y en las formulas 1B y 1C cuando menos uno de X1 a X4 es C, de preferencia dos de X1 a X4 son C; y es 0, 1, 2, o 3; z es 0, 1, 2, 3 o 4; R3, que solamente se puede enlazar a cualquiera de X1, X2, X4, y X4 es H, o de preferencia alquilo C1-7 insustituido o sustituido, alquenilo C2-7 insustituido o sustituido, alquinilo C2-7 insustituido o sustituido, arilo insustituido o sustituido,, heterociclilo insustituido o sustituido,, cicloalquilo insustituido o sustituido, halogeno, hidroxilo, hidroxilo eterificado o esterificado, mercapto insustituido o sustituido, sulfinilo insustituido o sustituido,, sulfonilo insustituido o sustituido, amino, amino mono- o di- sustituido, carboxilo, carboxilo esterificado o amidado, sulfamoilo insustituido o sustituido,, nitro o ciano, con la condicion de que si R3 es H, y y z son 0; R4 -si y o z es 2 o más, independientemente - se selecciona a partir de un grupo de sustituyentes que consisten en alquilo C1-7 insustituido o sustituido, alquenilo C2-7 insustituido o sustituido, alquinilo C2-7 insustituido o sustituido, halogeno, hidroxilo, hidroxilo eterificado o esterificado, mercapto insustituido o sustituido, sulfinilo insustituido o sustituido, sulfonilo insustituido o sustituido, amino, amino mono- o di-sustituido, carboxilo, carboxilo esterificado o amidado, sulfamoilo insustituido o sustituido, nitro, y ciano; T es metileno (-CH2-) o carbonilo (-C(=O)-), y R11 es H, hidroxilo, halogeno, alquilo C1-7, halo-alquilo C1-7, cicloalquilo, cicloalquilo sustituido por halogeno, alcoxilo C1-7, halo-alcoxilo C1-7, o ciano, o una sal del mismo.
ARP050105578A 2004-12-30 2005-12-28 Piperidinas 3,4-sustituidas AR052446A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0428526.8A GB0428526D0 (en) 2004-12-30 2004-12-30 Organic compounds

Publications (1)

Publication Number Publication Date
AR052446A1 true AR052446A1 (es) 2007-03-21

Family

ID=34179049

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105578A AR052446A1 (es) 2004-12-30 2005-12-28 Piperidinas 3,4-sustituidas

Country Status (21)

Country Link
US (2) US8084450B2 (es)
EP (2) EP1833816B1 (es)
JP (1) JP5188814B2 (es)
KR (1) KR20070091174A (es)
CN (1) CN101094848B (es)
AR (1) AR052446A1 (es)
AT (1) ATE448217T1 (es)
AU (1) AU2005321475B2 (es)
BR (1) BRPI0519769A2 (es)
CA (1) CA2587348A1 (es)
DE (1) DE602005017665D1 (es)
ES (1) ES2336470T3 (es)
GB (1) GB0428526D0 (es)
GT (1) GT200500359A (es)
MX (1) MX2007008078A (es)
PE (1) PE20061332A1 (es)
PL (1) PL1833816T3 (es)
PT (1) PT1833816E (es)
RU (1) RU2411239C2 (es)
TW (1) TW200635915A (es)
WO (1) WO2006069788A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0505969D0 (en) * 2005-03-23 2005-04-27 Novartis Ag Organic compounds
GB0510810D0 (en) * 2005-05-26 2005-06-29 Novartis Ag Organic compounds
AU2006253805A1 (en) * 2005-05-27 2006-12-07 Actelion Pharmaceuticals Ltd. Novel piperidine carboxylic acid amide derivatives
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
JP5306821B2 (ja) 2005-12-30 2013-10-02 ノバルティス アーゲー レニン阻害剤としての３，５−置換ピペリジン化合物
RU2425032C2 (ru) 2006-02-02 2011-07-27 Актелион Фармасьютикалз Лтд Вторичные амины в качестве ингибиторов ренина
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008093737A1 (ja) 2007-01-31 2008-08-07 Dainippon Sumitomo Pharma Co., Ltd. アミド誘導体
WO2008128832A1 (en) * 2007-04-18 2008-10-30 Nicox S.A. Nitroderivatives of non-peptidic renin inhibitors for the treatment of cardiovascular, renal and chronic liver disease, inflammations and metabolic syndrome
CA2688057A1 (en) * 2007-05-24 2008-11-27 Merck Frosst Canada Ltd. Novel case of renin inhibitors
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
EP2527338B1 (en) 2007-06-25 2015-05-06 Novartis AG N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
CN101842349B (zh) * 2007-11-01 2013-07-17 宇部兴产株式会社 磺酸苯酯化合物、使用它的非水电解液及锂电池
RU2010129690A (ru) * 2007-12-19 2012-01-27 Дайниппон Сумитомо Фарма Ко., Лтд. (Jp) Бициклические гетероциклические производные
WO2009127949A1 (en) * 2008-04-17 2009-10-22 Pfizer Inc. 4- [3- (aryloxy) benzylidene] -3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
JP4790871B2 (ja) 2008-05-05 2011-10-12 メルク フロスト カナダ リミテツド レニン阻害剤としての３，４−置換ピペリジン誘導体
PE20140858A1 (es) 2008-06-19 2014-08-04 Takeda Pharmaceutical Derivados de piperidina como inhibidores de renina
CN102203074A (zh) * 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
JP2012511514A (ja) * 2008-12-10 2012-05-24 メルク・カナダ・インコーポレイテツド レニン阻害剤としての３，４−置換ピペリジン誘導体
PL2443102T3 (pl) * 2009-06-19 2013-09-30 Basf Se Benzoksazynonowe środki chwastobójcze
EP2447264A4 (en) 2009-06-24 2012-12-12 Dainippon Sumitomo Pharma Co N-SUBSTITUTED CYCLIC AMINO DERIVATIVE
TWI472524B (zh) * 2009-09-28 2015-02-11 Actelion Pharmaceuticals Ltd 腎素抑制劑
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
EP2585048B1 (en) 2010-06-23 2018-04-11 CymaBay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
HUE037584T2 (hu) 2011-03-16 2018-09-28 Mitsubishi Tanabe Pharma Corp Nitrogéntartalmú telített heterociklusos vegyület
AU2013302390A1 (en) 2012-08-16 2015-02-26 Ohio State Innovation Foundation Stat3 inhibitors and their anticancer use
EP2933248B1 (en) * 2012-09-14 2018-01-31 Mitsubishi Tanabe Pharma Corporation Novel renin inhibitor
US20160137639A1 (en) * 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
FR3002736B1 (fr) * 2013-03-04 2015-06-26 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
CN103524511A (zh) * 2013-10-21 2014-01-22 南京邮电大学 2,7,12-三溴-5,10,15-三烷基三并咔唑的制备方法
CA3032432A1 (en) 2016-08-03 2018-02-08 Charles A. Mcwherter Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
CN111423411B (zh) * 2020-04-02 2021-04-16 南京生命源医药科技有限公司 一种新型肾素抑制剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278541A (en) * 1966-10-11 Di-substituted-n-alkyl piperidines
US4559337A (en) 1985-02-25 1985-12-17 G.D. Searle & Co. 8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-(alkoxy-containing acyl)hydrazides
TW224941B (es) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
EP0739204A4 (en) 1993-11-09 2000-03-15 Merck & Co Inc PIPERIDINE, PYRROLIDINE AND HEXAHYDRO-1H-AZEPINE SUPPORT THE RELEASE OF THE GROWTH HORMONE
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
JP3314938B2 (ja) * 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
IL123293A (en) * 1995-09-07 2003-06-24 Hoffmann La Roche Piperidine derivatives, their preparation and pharmaceutical compositions containing them
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6225352B1 (en) 1996-08-14 2001-05-01 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
JP4066004B2 (ja) * 1997-10-13 2008-03-26 忠弘 大見 上段部材取付けの基準となる孔を有する複数の下段部材の固定方法および固定用治具
EP1119553A1 (en) * 1998-10-07 2001-08-01 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
WO2000063173A1 (en) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
AU2002306848A1 (en) 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
NZ533603A (en) 2001-12-20 2007-02-23 Bristol Myers Squibb Co Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome
BR0309498A (pt) 2002-04-29 2005-02-15 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças que são relacionadas com o ras, e, uso de compostos
US20030216441A1 (en) 2002-05-10 2003-11-20 Gwaltney Stephen L. Farnesyltransferase inhibitors
PL375214A1 (en) * 2002-06-27 2005-11-28 Actelion Pharmaceuticals Ltd. Novel tetrahydropyridine derivatives as renin inhibitors
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
AU2004234040A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
EP1620403B1 (en) 2003-04-29 2007-11-28 Actelion Pharmaceuticals Ltd. Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives
JP2006524655A (ja) 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド ３−位にヘテロ原子を有する新規９−アザビシクロノネン誘導体
BRPI0409818A (pt) 2003-04-30 2006-05-09 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
WO2004096799A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd Tropane derivatives and their use as ace inhibitors
BRPI0409882A (pt) 2003-05-02 2006-05-23 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
US20070078164A1 (en) 2003-11-26 2007-04-05 Richard Sedrani 4-Phenylpiperidine derivatives as renin inhibitors
TW200613274A (en) 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PL1833816T3 (pl) 2010-04-30
PT1833816E (pt) 2010-02-17
US8084450B2 (en) 2011-12-27
WO2006069788A1 (en) 2006-07-06
US20090312304A1 (en) 2009-12-17
CN101094848A (zh) 2007-12-26
US8178559B2 (en) 2012-05-15
EP1833816B1 (en) 2009-11-11
RU2411239C2 (ru) 2011-02-10
CN101094848B (zh) 2013-03-13
MX2007008078A (es) 2007-07-24
PE20061332A1 (es) 2006-12-27
TW200635915A (en) 2006-10-16
RU2007129090A (ru) 2009-02-10
EP2177518A1 (en) 2010-04-21
JP5188814B2 (ja) 2013-04-24
US20110263560A1 (en) 2011-10-27
KR20070091174A (ko) 2007-09-07
ES2336470T3 (es) 2010-04-13
CA2587348A1 (en) 2006-07-06
GT200500359A (es) 2006-07-17
ATE448217T1 (de) 2009-11-15
EP1833816A1 (en) 2007-09-19
AU2005321475A1 (en) 2006-07-06
JP2008526701A (ja) 2008-07-24
GB0428526D0 (en) 2005-02-09
AU2005321475B2 (en) 2009-11-12
BRPI0519769A2 (pt) 2009-02-17
DE602005017665D1 (de) 2009-12-24

Similar Documents

Publication Publication Date Title
AR052446A1 (es) Piperidinas 3,4-sustituidas
CY1119101T1 (el) Ναφθαλινο-ισοξαζολινες ως παραγοντες καταπολεμισης ασπονδυλων παρασιτων
CO6220907A2 (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
CO5550398A2 (es) 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos
AR085908A1 (es) DERIVADOS DE 3-BUTIN-2-OL Y DE CARBONITRILO CON ACTIVIDAD INHIBIDORA DE LA QUINASA INDUCTORA DE NF-kB (NIK)
DOP2010000272A (es) Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion
DE60239884D1 (de) Pyrimidinverbindung und diese enthaltende medizinische zusammensetzung
ES2530398T3 (es) Pirrolidin-2-onas 4-sustituidas y su uso
CY1118344T1 (el) Αναστολεις απομεθυλασης-1 ειδικης για λυσινη και η χρηση αυτων
PE20050431A1 (es) Peptidos macrociclicos activos contra el virus de la hepatitis c
EA200970567A1 (ru) Противомикробная композиция для отделки текстиля
AR058776A1 (es) Compuesto de piridina condensado
EP2463352A3 (en) Light emitting device material and light emitting device
CY1114767T1 (el) Ν,ν-υποκατεστημενες ενωσεις 3-αμινοπυρρολιδινης χρησιμες ως αναστολεις επαναπροσληψης μονοαμινων
AR070263A1 (es) Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios.
PT1254135E (pt) Compostos organicos
UY30050A1 (es) Derivados de pirimido-oxazinil-fenilo, sales de los mismos, composiciones, preparaciones y aplicaciones
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR077486A2 (es) Compuesto derivado de isotiazol sustituido composicion fungicida insecticida acaricida molusquicida o nematicida quelo comprende y metodo para combatir y controlar hongos insectos acaros nematodos o moluscos usando dicho compuesto o dicha composicion
MX2019014406A (es) Compuesto heterociclico y composicion que contiene el mismo.
ES2182360T3 (es) Compuestos fotocromicos.
NO20071152L (no) Lysinbaserte forbindelser
DE60206030D1 (de) Azofarbstoffe
CO6331306A2 (es) Derivados de n-heterociclico-imidazo[1,2alfa]piridina-2-carboxamidas su preparacion y su aplicacion en terapeutica
CO5590952A2 (es) Derivados de aminoacetonitrilo y su uso para controlar parasitos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal